Allergan (AGN) Posts Q3 EPS of $1.13, Topping Street; Guides FY09
More News related to AGN
- Spectrum Pharma (SPPI) and Handok Pharma Announce Plans for Apaziquone Development in South Korea
- 2010 IR Global Rankings: Invitation for Investors and Analysts Vote for Companies with the Best IR Program and for the Best IR Officer
- Spectrum Pharma (SPPI) To Collaborate with Nippon Kayaku to Develop and Commercialize Apaziquone in Asia
- The Lowe Law Firm Files Suit over Alleged Botox Overdose
- Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Opthalmic Solution
Allergan (NYSE: AGN) reports Q3 EPS of $1.13, versus the analyst estimate of $0.70. Revenue for the quarter was $1.13 billion, which compares to the estimate of $1.08 billion.
Sees FY09 sales of $4.35-$4.4 billion, and EPS of $2.75 - $2.77/share.
Related Categories
EarningsGuidance
Stocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
